Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Developmental therapeutics

659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors


23 Oct 2023


Mini oral session - Developmental therapeutics


Clinical Research

Tumour Site

Urothelial Cancer


Jian Zhang


Annals of Oncology (2023) 34 (suppl_2): S458-S497. 10.1016/S0923-7534(23)01936-1


J. Zhang1, R. Liu2, S. Gao1, X. Li3, J. Chen4, X. Yao5, Y. fang6, R. Li7, M. Zhang8, F. Qiu9, Y. Li10, T. Liu11, H. Huang12, X. Zhang13, H. Guo14, B. Hu15, J. Liu16, Q. Yang17, P. Zhao18, P. Wang19

Author affiliations

  • 1 Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center, 201135 - Shanghai/CN
  • 2 Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 3 Department Of Oncology, The First Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 4 Department Of Medical Oncology, Yantai Yuhunagding Hospital, 264013 - Yantai/CN
  • 5 Department Of Urologic Oncology, Tianjin Cancer Hospital, 300060 - Tianjin/CN
  • 6 Department Of Urology, Affiliated Cancer Hospital of Chongqing University, 400038 - Chongqing/CN
  • 7 Gynecological Oncology Center, Chongqing University Cancer Hospital, Chongqing/CN
  • 8 Department Of Medical Oncology, The Second Hospital of Anhui Medical University, 230032 - Hefei/CN
  • 9 Department Of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, 310009 - Hangzhou/CN
  • 10 Department Of Oncology, Shenyang Tenth People's Hospital, 110001 - Shenyang/CN
  • 11 Department Of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN
  • 12 Department Of Urinary Surgery, The First Affiliated Hospital of Wenzhou Medical University - Nanbaixiang Site, 325003 - Wenzhou/CN
  • 13 Department Of Urology, Wuhan Union Hospital, 430021 - Wuhan/CN
  • 14 Department Of Urology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 210008 - Nanjing/CN
  • 15 Department Of Urology, Liaoning Cancer Hospital and Institute, Shenyang/CN
  • 16 Department Of Biotherapy, West China School of Medicine/West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 17 Phase Ⅰ Clinical Trial Center, The Second Affiliated Hospital of Sun Yat-sen University, 510308 - Guangzhou/CN
  • 18 Department Of Medical Oncology, The First Affiliated Hospital of Medical School of Zhejiang University, 310003 - Hangzhou/CN
  • 19 Clinical Medicine Department, Mabwell (Shanghai) Bioscience Co., Ltd., 201210 - Shanghai/CN


This content is available to ESMO members and event participants.

Abstract 659MO


Nectin-4 is an adhesion molecule that highly expressed in variety of solid tumors and could be a potent therapeutic target. 9MW2821 is a monoclonal antibody-drug conjugate (ADC) that delivers monomethyl auristatin E to cells expressing Nectin-4. Here we report the first-in-human, multicenter, phase I/II study designed to explore the safety, pharmacokinetics and efficacy of 9MW2821 in advanced solid tumors.


9MW2821 was administered by intravenous infusion on days 1, 8 and 15 of each 28-day cycle. The study included dose escalation, dose expansion and cohort expansion period which included urothelial cancer (UC) and other Nectin-4 positive solid tumors. Primary objectives were assessment of safety and preliminary efficacy.


As of April 27, 2023, 97 patients (pts) were enrolled with doses ranging from 0.33 to 1.5mg/kg. Median age was 57 years (range, 32-78). Only 1 dose limiting toxicity of grade 4 neutropenia lasted more than 5 days was observed at 1.5mg/kg group. Maximum tolerated dose was not yet reached. Treatment related adverse events (TRAEs) of any grade occurred in 64.9% pts. The most common TRAEs were white blood cell (WBC) count decreased (36.1%), neutropenia (35.1%), nausea (22.7%), aspartate aminotransferase increased (22.7%), rash (19.6%), alopecia (19.6%), fatigue (18.6%), decreased appetite (18.6%), anemia (17.5%), vomiting (16.5%), peripheral sensory neuropathy (16.5%). Grade 3/4 TRAEs occurred in 35.1% pts. The most common grade 3/4 TRAEs were WBC count decreased (18.6%) and neutropenia (18.6%). Treatment related death was not observed. Among 39 pts treated with 9MW2821 at 1.25mg/kg or above and evaluable for tumor assessment, objective response rate (ORR) and disease control rate (DCR) was 38.5% and 84.6%, respectively. In 18 pts with UC who progressed after platinum-based chemotherapy and immune checkpoint inhibitors and dosed at 1.25mg/kg, ORR and DCR was 55.6% and 94.4%, respectively. Objective responses were also observed in pts with breast cancer and cervical cancer.


The results showed that 9MW2821 had manageable safety profile and promising antitumor activity. Enrollment continues to determine efficacy of 9MW2821 in certain solid tumors.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Mabwell (Shanghai) Bioscience Co., Ltd.


Mabwell (Shanghai) Bioscience Co., Ltd.


P. Wang: Financial Interests, Institutional, Full or part-time Employment: Mabwell (Shanghai) Bioscience Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.